TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$9.70 +0.25 (+2.65%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesBuy This Stock About Knight Therapeutics Stock (TSE:GUD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's RangeC$9.45▼C$9.9850-Day RangeC$7.38▼C$9.7052-Week RangeC$5.66▼C$9.98Volume148,001 shsAverage Volume93,935 shsMarket CapitalizationC$952.34 millionP/E Ratio161.67Dividend YieldN/APrice TargetC$9.50Consensus RatingBuy Company Overview Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Read More Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUD Stock News HeadlinesKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comKnight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines. But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.June 29 at 1:00 AM | Behind the Markets (Ad)TSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comKnight Therapeutics Secures US$100 Million Credit Facility to Boost GrowthOctober 31, 2025 | msn.comSee More Headlines GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$6.05 at the start of the year. Since then, GUD stock has increased by 60.3% and is now trading at C$9.70. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) released its quarterly earnings results on Thursday, May, 7th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $147.59 million for the quarter. Knight Therapeutics had a trailing twelve-month return on equity of 0.73% and a net margin of 1.10%. Read the conference call transcript. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU). Company Calendar Last Earnings5/07/2026Today6/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Price Target for Knight TherapeuticsC$9.50 High Price TargetC$9.50 Low Price TargetC$9.50 Potential Upside/Downside-2.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C$0.06 Trailing P/E Ratio161.67 Forward P/E Ratio96.09 P/E Growth-1013.5Net Income-C$30.73 million Net Margins1.10% Pretax MarginN/A Return on Equity0.73% Return on Assets0.51% Debt Debt-to-Equity Ratio8.86 Current Ratio2.32 Quick Ratio1.79 Sales & Book Value Annual SalesC$510.45 million Price / Sales1.87 Cash FlowC$2.52 per share Price / Cash Flow3.85 Book ValueC$8.00 per share Price / Book1.21Miscellaneous Outstanding Shares98,179,000Free FloatN/AMarket CapC$952.34 million OptionableNot Optionable Beta-0.14 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (TSE:GUD) was last updated on 6/29/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe wait is finally overBiotech analyst Jeff Brown is going on record: a rare convergence of three forces is set to hit by July 23, tr...Brownstone Research | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe BNZI Story Is Evolving with a Zack’s BUY!Banzai International (NASDAQ: BNZI) just earned a Zacks Rank No. 2 (Buy) upgrade, reflecting growing confidenc...Huge Alerts | SponsoredTomorrow morning's stock alertOur research analysts are set to release their next stock idea tomorrow morning just before 12:00 PM Eastern. ...The Early Bird | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GUD Stock Alerts